Summary
Published in bioRxiv (2025), this peer-reviewed study used 3D Petri Dish® micro-molds to form scaffold-free 3D microtissues. Full citation: Sharma, Saurabh, et al. Antibody-Free Immunopeptide Nano-Conjugates for Brain-Targeted Drug Delivery in Glioblastoma Multiforme
Antibody-Free Immunopeptide Nano-Conjugates for Brain-Targeted Drug Delivery in Glioblastoma Multiforme
Research Overview
Glioblastoma multiforme carries a mean survival under eight months, a figure largely unchanged for decades, and the blood-brain barrier keeps most modern immunotherapy from reaching these tumors at all.
This study introduced an actively targeted immunotherapeutic nanoconjugate designed to cross the barrier by LRP-1 receptor-mediated transcytosis — an antibody-free approach using immunopeptides rather than full antibodies. The design aims to deliver immune-modulating activity into the central nervous system, addressing the delivery problem that has limited immunotherapy against brain tumors.
Key Discoveries
- Antibody-free immunopeptide nanoconjugate designed to cross the blood-brain barrier
- Uses LRP-1 receptor-mediated transcytosis for active brain targeting
- Targets glioblastoma, where mean survival has stayed under 8 months for decades
